Latest market price
24.26
+0.43+1.80%
NRCQT67NRC Health·NASDAQ
24.26+1.80%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
Index—P/E86.64EPS (ttm)0.28Insider Own—Shs Outstand22.12MPerf Week8.06%
Market Cap536.62MForward P/E21.86EPS next Y1.11Insider Trans0.00%Shs Float11.34MPerf Month19.21%
Enterprise Value635.62MPEG—EPS next Q0.25Short Float6.40%Perf Quarter23.84%
Income7.00MP/S3.75EPS this Y29.25%Short Ratio6.22Perf Half Y33.15%
Sales143.00MP/B—EPS next Y-18.98%ROA4.63%Short Interest725.58KPerf YTD29.25%
Book/sh-0.41P/C134.18EPS next 5Y-7.98%ROE—52W High24.75 -1.98%Perf Year85.19%
Cash/sh0.18P/FCF29.81EPS past 3/5Y-25.74% -18.54%ROIC9.54%52W Low11.74 106.64%Perf 3Y-42.39%
Dividend Est.0.64 (2.64%)EV/EBITDA25.42Sales past 3/5Y-3.40% 0.59%Gross Margin47.87%Volatility5.10% 4.10%Perf 5Y-44.32%
Dividend TTM0.64 (2.64%)EV/Sales4.44EPS Y/Y TTM-59.96%Oper. Margin11.06%ATR (14)0.97Perf 10Y49.75%
Dividend Ex-DateDec 29, 2026Quick Ratio0.64Sales Y/Y TTM2.14%Profit Margin4.48%RSI (14)68.63Recom2.00
Dividend Gr. 3/5Y-14.77% 19.88%Current Ratio0.64EPS Q/Q-8.70%SMA2013.54%Beta0.23Target Price—
Payout209.19%Debt/Eq—Sales Q/Q8.57%SMA5014.12%Rel Volume0.88Prev Close23.83
Employees357LT Debt/Eq—EarningsFeb 02SMA20026.43%Avg Volume114.72KPrice24.26
IPO DateMay 23, 2013Option/ShortYes / YesEPS/Sales Surpr.16.67% —Net Debt/EBITDA3.96Volume101,205Change1.80%
Latest News· Times ET
Oct-30-26
Oct-28-26
Oct-27-26
Oct-27-2606:05PM
Oct-26-26
Oct-25-26
Oct-22-26
Oct-19-26
Oct-18-26
Oct-15-26
Oct-13-26
Company

National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue143137143149—————
Cost of Goods Sold Incl. D&A75605756—————
Gross Profit69778693—————
Selling, General and Administrative Excl. Other50554547—————
Research and Development
0000—————
Other Operating Expense2066—————
Operating Income17233540—————
Interest Expense5531—————
Unusual Expense
—————————
Non-Operating Income (Expense)0001—————
Net Income Before Taxes9183340—————
Income Taxes4689—————
Consolidated Net Income7122531—————
Net Income From Continuing Operations7122531—————
Net Income7122531—————
EPS (Recurring)0.300.521.051.26—————
EPS (Basic, Before Extraordinaries)0.300.521.051.26—————
EPS (Diluted)0.280.521.041.25—————
EBITDA25304146—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio86.6436.1016.9631.65—————
Price To Sales Ratio3.733.012.966.64—————
Gross Margin48.2556.2060.1462.42—————
Operating Margin11.8916.7924.4826.85—————
Net Margin4.908.7617.4820.81—————
Shares Outstanding22222425—————
Market Capitalization534413423989—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$26.19$22.01$17.84$13.67$9.49● Close Price0.00K24.54K49.08K73.62K98.16KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
HARRISON SHANE REVP & Chief Financial OfficerFeb 17 '26Buy12.278,00098,1628,000Feb 19
Hays Michael D.ChairmanJan 05 '26Option Exercise15.239,145139,27820,154Jan 07
Hrdy HelenEVP & Chief Operating OfficerDec 15 '25Option Exercise15.2312,346188,030151,762Dec 17
Freeman Jordan NicoleChief Accounting OfficerJul 31 '25Buy12.9777110,000771Aug 04
BEANS PATRICK E10% OwnerMay 12 '25Buy13.592,50033,97435,003May 13
Hays Michael D.CEO & PresidentJan 02 '25Option Exercise13.1710,014131,88411,009Jan 06
NUNNELLY JOHN NDirectorMar 27 '24Option Exercise14.959,259138,42236,153Mar 29
Common Property Trust10% OwnerMar 01 '24Sale40.54598,65324,269,3933,854,284Mar 05
Amandla MK Trust10% OwnerJan 05 '24Sale40.202,614105,0923,831,362Jan 08
Amandla MK Trust10% OwnerJan 04 '24Sale41.224,600189,6173,833,976Jan 08
Common Property Trust10% OwnerJan 03 '24Sale41.53364,62515,142,8764,452,937Jan 05
Amandla MK Trust10% OwnerJan 03 '24Sale41.77120,1395,018,7593,838,576Jan 04
Hays Michael D.CEO & PresidentJan 02 '24Option Exercise18.802,90454,5952,904Jan 04
Amandla MK Trust10% OwnerJan 02 '24Sale40.31201,1008,106,2463,958,715Jan 04
Amandla MK Trust10% OwnerDec 14 '23Sale41.5960024,9544,159,815Dec 14
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.